THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE
https://doi.org/10.20996/1819-6446-2012-8-2-211-219
Abstract
A comparison of ivabradine and omega-3 polyunsaturated fatty acids, drugs with principally different mechanisms of action, is presented in patients with chronic heart failure (CHF) on the base of GISSI-HF and SHIFT trails results. It is essential to compaire an effect of these drugs on the morbidity and mortality in combined therapy of patients with CHF , because each additional drug may change in compliance to treatment, induces additional costs or may be a reason of new side effects. Additional (to standard therapy) effects of ivabradine and omega-3 polyunsaturated fatty acids are discussed.
About the Authors
S. N. Tereshchenko
Research Institute for Clinical Cardiology named after A.L. Myasnikov , Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
I. V. Zhirov
Research Institute for Clinical Cardiology named after A.L. Myasnikov , Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
A. G. Kochetov
Research Institute for Cerebrovascular Disease and Stroke, Russian National Research Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
O. V. Uspenskaya
Research Institute for Clinical Cardiology named after A.L. Myasnikov , Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
References
1. Никулина Н.Н., Якушин С.С., Бойцов С.А., и др. Проблемы статистической регистрации смертности от ХСН в Российской Федерации. Тезисы III конгресса «Сердечная недостаточность 2008». Москва: ОССН; 2008: 53.
2. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН. Сердечная Недостаточность 2006;7(3):112–115.
3. Фомин И.В. Результаты 9-летнего наблюдения больных, включенных в эпидемиологическое исследование хронической сердечной недостаточности в Европейской части Российской Федерации — ЭПОХА-ХСН. Тезисы III конгресса «Сердечная недостаточность 2008». Москва: ОССН; 2008: 8.
4. Cook D.J., Sackett D.L., Spitzer W. Methodologic guidelines for systematic reviews of randomized controlled trials in health care from the Potsdam consultation on meta-analysis. J Clin Epidemiol 1995;48:167–71.
5. Bero L., Rennie D. The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995;274:1935–8.
6. Huston P . The Cochrane Collaboration helping unravel tangled web woven by international research. Can Med Assoc J 1996;154:1389–92.
7. Sacks H.S., Berrier J., Reitman D., et al. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450–5.
8. Sacks H.S., Reitman D., Pagano D., Kupelnick B. Meta-analysis: an update. Mt Sinai J Med 1996;63:216–24.
9. Jadad A.R., Cook D.J., Browman G. A guide to interpreting discordant systematic reviews. Can Med Assoc J 1997;156:1411–6.
10. LeLorier J., Gregroire G., Benhaddad A., et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536–42.
11. Swedberg K., Komajda M., Böhm M., et al., on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875–885.
12. Effect of ω-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebocontrolled trial. Lancet 2008; 372: 1223–30.
13. Петри А., Сэбин К. Наглядная медицинская статистика. Москва:Г эотар-Медиа; 2010.
14. Brown L. D., Cai T. T., Dasgupta A. Interval estimation for a binomial proportion. Statistical science 2001; 2: 101–133.
15. Garcia-Perez M. A. On the confidence interval for the binomial parameter . Quality and quantity 2005; 39: 467–481.
16. Wilson E. B. Probable inference, the law of succession, and statistical inference. Journal of American Statistical Association 1927; 22: 209–212.
17. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008; 372: 817–821.
18. Drouin A, Gendron ME, Thorin E, et al. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 2008;154:749–757.
19. Mulder P , Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674–1679.
20. Teerlink J.R. Ivabradine in heart failure—no paradigm SHIFT…yet. Lancet 2010, 376: 847–849.
21. Gheorgiade M. Omega-3 PUFAs for heart failure up LVEF , cut remodeling, in rare mechanistic study. Abstracts of the Heart Failure Society of America 14th Annual Scientific. September 12–15, 2010; San Diego, California, USA.
22. National guidelines for diagnosis and treatment of chronic heart failure (third revision). Serdechnaya Nedostatochnost' 2010; 11(1): 1–57. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (третий пересмотр). Сердечная Недостаточность 2010; 11(1): 1–57).
Review
For citations:
Tereshchenko S.N., Zhirov I.V., Kochetov A.G., Uspenskaya O.V. THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE. Rational Pharmacotherapy in Cardiology. 2012;8(2):211-219. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-2-211-219
Views: 1649
Email this article 